Literature DB >> 19826875

Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas.

Shinji Itoh1, Kazutoyo Morita, Shigeru Ueda, Keishi Sugimachi, Yo-ichi Yamashita, Tomonobu Gion, Kengo Fukuzawa, Kenzo Wakasugi, Akinobu Taketomi, Yoshihiko Maehara.   

Abstract

BACKGROUND: Recently, local ablation therapy has been widely used for treatment of small hepatocellular carcinoma (HCC). The present study assessed the outcome of hepatic resection combined with intraoperative local ablation therapy in patients with multinodular HCCs.
METHODS: Forty-one patients with initial and multinodular HCCs underwent hepatic resection combined with intraoperative local ablation therapy. The mean maximum diameter of all tumors was 3.8 cm (range 2.1-16.0 cm), and the mean number of nodules was 3.2 (range 2-11). We evaluated the survival rates and assessed the prognostic factors associated with overall survival rates using Cox proportional hazard models.
RESULTS: Intraoperative local ablation therapy was completed in all patients with no evidence of residual viable tumor on the first postoperative computed tomography (CT) scan. The 3-, 5- and 7-year overall survival rates were 84.3%, 61.2%, and 61.2%, respectively. Patients with preoperative des-gamma carboxyprothrombin (DCP) level >300 mAU/ml showed significantly worse overall survival than those with DCP level <or=300 mAU/ml (P < 0.01).
CONCLUSIONS: Hepatic resection combined with intraoperative local ablation therapy is effective for multinodular HCCs. DCP >300 mAU/ml was a significant prognostic factor of long-term overall survival.

Entities:  

Mesh:

Year:  2009        PMID: 19826875     DOI: 10.1245/s10434-009-0721-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

2.  Impact of the VIO system in hepatic resection for patients with hepatocellular carcinoma.

Authors:  Shinji Itoh; Kengo Fukuzawa; Yuki Shitomi; Masahiro Okamoto; Tadahiko Kinoshita; Akinobu Taketomi; Ken Shirabe; Kenzo Wakasugi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-09-20       Impact factor: 2.549

Review 3.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

4.  Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.

Authors:  Xi Xu; Xingyu Pu; Li Jiang; Yang Huang; Lunan Yan; Jiayin Yang; Tianfu Wen; Bo Li; Hong Wu; Wentao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-27       Impact factor: 4.553

5.  Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.

Authors:  Norifumi Iseda; Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Takeo Toshima; Yoshihiro Nagao; Noboru Harada; Yoshinao Oda; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2021-07-12       Impact factor: 3.402

6.  Slow Gait Speed Is a Risk Factor for Complications After Hepatic Resection.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Kazuhisa Sakata; Takashi Motomura; Yohei Mano; Takeo Toshima; Norifumi Harimoto; Noboru Harada; Toru Ikegami; Yuji Soejima; Ryuichi Kusaba; Takahide Kamishima; Akihiro Nishie; Yoshihiko Maehara
Journal:  J Gastrointest Surg       Date:  2018-10-08       Impact factor: 3.452

7.  Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma.

Authors:  Cheng Zhou; Yuanfei Peng; Kaiqian Zhou; Lan Zhang; Xiangyu Zhang; Lei Yu; Jie Hu; Feiyu Chen; Shuangjian Qiu; Jian Zhou; Jia Fan; Zhenggang Ren; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-02       Impact factor: 7.293

8.  Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.

Authors:  Norifumi Iseda; Shinji Itoh; Katsuya Toshida; Takahiro Tomiyama; Akinari Morinaga; Masahiro Shimokawa; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Takeo Toshima; Yoshihiro Nagao; Noboru Harada; Tomoharu Yoshizumi; Masaki Mori
Journal:  Cancer Sci       Date:  2022-05-26       Impact factor: 6.518

9.  The evolution of surgical treatment for gastrointestinal cancers.

Authors:  Yoshihiko Maehara; Yuji Soejima; Tomoharu Yoshizumi; Naoyuki Kawahara; Eiji Oki; Hiroshi Saeki; Tomohiko Akahoshi; Toru Ikegami; Yo-Ichi Yamashita; Tadashi Furuyama; Keishi Sugimachi; Noboru Harada; Tetsuzo Tagawa; Norifumi Harimoto; Shinji Itoh; Hideto Sonoda; Koji Ando; Yuichiro Nakashima; Yoshihiro Nagao; Nami Yamashita; Yuta Kasagi; Takafumi Yukaya; Takeshi Kurihara; Ryosuke Tsutsumi; Shinkichi Takamori; Shun Sasaki; Tetsuo Ikeda; Yoshikazu Yonemitsu; Takasuke Fukuhara; Hiroyuki Kitao; Makoto Iimori; Yuki Kataoka; Takeshi Wakasa; Masami Suzuki; Koji Teraishi; Yasuto Yoshida; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2019-09-14       Impact factor: 3.402

10.  Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Norifumi Iseda; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Yoshihiro Nagao; Takeo Toshima; Noboru Harada; Akihiro Nishie; Kousei Ishigami; Masaki Mori
Journal:  JGH Open       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.